Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Bak

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Journal of Human Hypertension|December 1, 1995
Long-term moderate sodium restriction does not adversely affect the serum HDL/total cholesterol ratioJ M Geleijnse, J C Witteman, A A Bak, et al.
The American Journal of Clinical Nutrition|December 10, 2008
Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjectsKim van der Zander, Michiel L Bots, Annette A A Bak, et al.
Clinical Chemistry and Laboratory Medicine|January 13, 2001
Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general populationW M Janssen, H Hillege, S J Pinto-Sietsma, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 29, 1998
[Antithrombotic treatment following acute ischemic heart disease: acetylsalicylic acid and (or) oral anticoagulants?; ASPECT-II, a new study]R F van Es, D E Grobbee, J W Deckers, et al.
Atherosclerosis|October 5, 2001
The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trialA E Hak, A A Bak, J Lindemans, et al.
Journal of Clinical Epidemiology|July 1, 1997
Efficiency optimization of the selection period in therapeutic trialsC K Moons, G A van Es, T Stijnen, et al.
The American Journal of Cardiology|September 12, 2000
Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT])G F Diercks, W M Janssen, A J van Boven, et al.
European Journal of Epidemiology|September 4, 2003
The Atherosclerosis Risk in Young Adults (ARYA) study: rationale and designA Oren, L E Vos, C S P M Uiterwaal, et al.
Maturitas|October 9, 1999
Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thicknessM J de Kleijn, M L Bots, A A Bak, et al.
Maturitas|September 28, 2001
Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal womenM E Ossewaarde, M L Bots, A A Bak, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of Human Hypertension|December 1, 1995
Long-term moderate sodium restriction does not adversely affect the serum HDL/total cholesterol ratioJ M Geleijnse, J C Witteman, A A Bak, et al.
The American Journal of Clinical Nutrition|December 10, 2008
Enzymatically hydrolyzed lactotripeptides do not lower blood pressure in mildly hypertensive subjectsKim van der Zander, Michiel L Bots, Annette A A Bak, et al.
Clinical Chemistry and Laboratory Medicine|January 13, 2001
Low levels of urinary albumin excretion are associated with cardiovascular risk factors in the general populationW M Janssen, H Hillege, S J Pinto-Sietsma, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 29, 1998
[Antithrombotic treatment following acute ischemic heart disease: acetylsalicylic acid and (or) oral anticoagulants?; ASPECT-II, a new study]R F van Es, D E Grobbee, J W Deckers, et al.
Atherosclerosis|October 5, 2001
The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trialA E Hak, A A Bak, J Lindemans, et al.
Journal of Clinical Epidemiology|July 1, 1997
Efficiency optimization of the selection period in therapeutic trialsC K Moons, G A van Es, T Stijnen, et al.
The American Journal of Cardiology|September 12, 2000
Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT])G F Diercks, W M Janssen, A J van Boven, et al.
European Journal of Epidemiology|September 4, 2003
The Atherosclerosis Risk in Young Adults (ARYA) study: rationale and designA Oren, L E Vos, C S P M Uiterwaal, et al.
Maturitas|October 9, 1999
Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thicknessM J de Kleijn, M L Bots, A A Bak, et al.
Maturitas|September 28, 2001
Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal womenM E Ossewaarde, M L Bots, A A Bak, et al.
Pageof 3